Article
Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Cancer biomarkers : section A of Disease markers - 1 Jan 2018
Wang Xiaohui, Qu Huajun, Dong Yinghe, Wang Guozhi, Zhen Yuchen, Zhang Linxia
Abstract excerpt
Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug resistance remains a challenge. To define molecular mechanisms of vemurafenib resistance, we generated A375-R, WM35-R cell lines resistant to vemurafenib and show that the phosphorylated (p)-STAT3 was upregulated in these cells in vitro and in vivo. In particular, activation of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.